These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 27745954)

  • 61. Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.
    Sun W; Roland KL; Kuang X; Branger CG; Curtiss R
    Infect Immun; 2010 Mar; 78(3):1304-13. PubMed ID: 20086087
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.
    Arlen PA; Singleton M; Adamovicz JJ; Ding Y; Davoodi-Semiromi A; Daniell H
    Infect Immun; 2008 Aug; 76(8):3640-50. PubMed ID: 18505806
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.
    Wang S; Heilman D; Liu F; Giehl T; Joshi S; Huang X; Chou TH; Goguen J; Lu S
    Vaccine; 2004 Sep; 22(25-26):3348-57. PubMed ID: 15308359
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A single dose sub-unit vaccine protects against pneumonic plague.
    Williamson ED; Eley SM; Stagg AJ; Green M; Russell P; Titball RW
    Vaccine; 2000 Oct; 19(4-5):566-71. PubMed ID: 11027822
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rational considerations about development of live attenuated Yersinia pestis vaccines.
    Sun W; Curtiss R
    Curr Pharm Biotechnol; 2013; 14(10):878-86. PubMed ID: 24372254
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis.
    Wang X; Singh AK; Zhang X; Sun W
    Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32152195
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.
    Thomas RJ; Webber D; Collinge A; Stagg AJ; Bailey SC; Nunez A; Gates A; Jayasekera PN; Taylor RR; Eley S; Titball RW
    Infect Immun; 2009 Apr; 77(4):1315-23. PubMed ID: 19188359
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.
    Kumar D; Kirimanjeswara G; Metzger DW
    Clin Vaccine Immunol; 2011 Nov; 18(11):1925-35. PubMed ID: 21880856
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.
    Palin A; Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
    Vaccine; 2007 Jan; 25(4):741-50. PubMed ID: 16959385
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.
    Eisele NA; Anderson DM
    Clin Vaccine Immunol; 2009 Dec; 16(12):1720-7. PubMed ID: 19828767
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066).
    Frey SE; Lottenbach K; Graham I; Anderson E; Bajwa K; May RC; Mizel SB; Graff A; Belshe RB
    Vaccine; 2017 Dec; 35(48 Pt B):6759-6765. PubMed ID: 29037578
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Protecting against plague: towards a next-generation vaccine.
    Williamson ED; Oyston PC
    Clin Exp Immunol; 2013 Apr; 172(1):1-8. PubMed ID: 23480179
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.
    Mizel SB; Graff AH; Sriranganathan N; Ervin S; Lees CJ; Lively MO; Hantgan RR; Thomas MJ; Wood J; Bell B
    Clin Vaccine Immunol; 2009 Jan; 16(1):21-8. PubMed ID: 18987167
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immune defense against pneumonic plague.
    Smiley ST
    Immunol Rev; 2008 Oct; 225():256-71. PubMed ID: 18837787
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
    Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
    Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice.
    Alvarez ML; Pinyerd HL; Crisantes JD; Rigano MM; Pinkhasov J; Walmsley AM; Mason HS; Cardineau GA
    Vaccine; 2006 Mar; 24(14):2477-90. PubMed ID: 16442673
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB; Bhat AA; Sah A; Donthamshetty RN
    Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.